SYDNEY and NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- EnGeneIC Limited today announced it has been recognized with the Breakthrough in glioblastoma Biotech Award 2026 at the Northwell Foundation, Lenox Hill Neurosurgery Brain Tumor Center Gala event in New York City. The award was presented to Joint-CEO’s and co-inventors Dr. Himanshu Brahmbhatt and Dr. Jennifer MacDiarmid on June 4, 2026.

The award recognizes EnGeneIC’s advancement of novel cyto-immunotherapy using its proprietary EnGeneIC Dream Vector (EDV™) nanocell platform. The technology is designed to bypass the blood brain barrier, selectively target tumors, deliver potent therapeutic payloads inside cancer cells, and activate both innate and adaptive tumor-specific immune responses, offering a fundamental shift in the approach to precision oncology in the treatment of glioblastoma with potential across multiple difficult-to-treat cancers.